Search Result

Results for "

Heart Failure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Acetyl-CoA Carboxylase (1) Adenosine Receptor (6) Adenylate Cyclase (1) Adrenergic Receptor (66) Akt (19) AMPK (9) Angiotensin Receptor (26) Angiotensin-converting Enzyme (ACE) (52) Anion Exchangers (1) Antibiotic (5) AP-1 (5) Apelin Receptor (APJ) (7) Apoptosis (41) Arrestin (4) ATP Synthase (1) Aurora Kinase (1) Autophagy (21) Bacterial (9) Bcl-2 Family (4) Biochemical Assay Reagents (3) Calcium Channel (21) Carbonic Anhydrase (4) Casein Kinase (4) Caspase (10) CHIKV (1) Chloride Channel (1) Cholinesterase (ChE) (2) COX (1) CRAC Channel (2) Creatine Kinase (1) CX3CR1 (1) Cytochrome P450 (2) Dengue Virus (2) DNA Alkylator/Crosslinker (1) Dopamine Receptor (4) Drug Derivative (5) Drug Intermediate (3) Drug Metabolite (15) E1/E2/E3 Enzyme (2) Elastase (1) Endogenous Metabolite (33) Endothelin Receptor (9) Enterovirus (2) Environmental Pollutants (1) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) Exosomes (2) Ferroptosis (1) Flavivirus (2) Fluorescent Dye (2) Formyl Peptide Receptor (FPR) (2) Fungal (1) FXR (2) G Protein-coupled Receptor Kinase (GRK) (20) GABA Receptor (5) GHSR (1) Glutathione Peroxidase (2) GSK-3 (1) Guanylate Cyclase (8) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) Histone Demethylase (2) HSV (2) IGF-1R (1) IKK (2) Imidazoline Receptor (8) Integrin (3) Interleukin Related (9) Isotope-Labeled Compounds (43) JAK (1) JNK (8) Ketohexokinase (1) LDLR (8) Leukotriene Receptor (1) Lysyl Oxidase (1) mAChR (1) MAP3K (3) Mas-related G-protein-coupled Receptor (MRGPR) (1) MDM-2/p53 (2) MicroRNA (4) Mineralocorticoid Receptor (7) Mitochondrial Metabolism (1) MMP (6) Monoamine Oxidase (1) Monocarboxylate Transporter (1) mTOR (7) Myosin (3) Na+/Ca2+ Exchanger (2) Na+/H+ Exchanger (NHE) (1) Na+/K+ ATPase (7) Natriuretic Peptide Receptor (NPR) (6) Neprilysin (13) Neuropeptide Y Receptor (1) NF-κB (14) NKCC (9) NO Synthase (9) NOD-like Receptor (NLR) (2) Nucleoside Antimetabolite/Analog (2) Opioid Receptor (1) P-glycoprotein (2) P2X Receptor (1) p38 MAPK (4) PAI-1 (1) Parasite (6) PD-1/PD-L1 (1) PDHK (2) Phosphatase (1) Phosphodiesterase (PDE) (24) PI3K (8) PKA (4) PKC (11) PKD (1) Porcupine (2) Potassium Channel (11) PPAR (2) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (14) Reference Standards (69) Renin (3) ROCK (4) ROS Kinase (2) RSV (1) RXFP Receptor (13) SARS-CoV (4) Sirtuin (1) SOD (1) Sodium Channel (3) Src (1) STAT (2) Survivin (1) TGF-beta/Smad (4) TGF-β Receptor (3) Thrombin (4) Thyroid Hormone Receptor (2) TNF Receptor (1) Toll-like Receptor (TLR) (4) Topoisomerase (5) Trace Amine-associated Receptor (TAAR) (2) Transthyretin (TTR) (1) TRP Channel (5) Tyrosinase (1) Urea Transporter (3) Vasopressin Receptor (8) VEGFR (2) Virus Protease (1) Wnt (4)
By Research Areas:	Cancer (110) Cardiovascular Disease (441) Endocrinology (51) Infection (26) Inflammation/Immunology (57) Metabolic Disease (75) Neurological Disease (52)
Oligonucleotides:	Guanine Nucleotide (1) Nucleotide Analogs (1) Antisense Oligonucleotides (2)

488

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18204

Valsartan 20+ Cited Publications CGP 48933	Angiotensin Receptor	Cardiovascular Disease Endocrinology
Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research .

HY-113071A

Mevalonic acid lithium salt 5+ Cited Publications MVA lithium salt	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-15407

Sacubitril 3 Publications Verification AHU-377	Neprilysin	Infection Cardiovascular Disease
Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC₅₀ of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19 .

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-103045

CMPD101 4 Publications Verification	ROCK PKC G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC₅₀ of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC₅₀s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure .

HY-B0203

Nebivolol 3 Publications Verification R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-15407B

Sacubitril sodium 3 Publications Verification AHU-377 sodium	Neprilysin	Infection Cardiovascular Disease
Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC₅₀ of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19 .

HY-139485

BMS-986224	Apelin Receptor (APJ)	Cardiovascular Disease
BMS-986224 is a potent, selective and orally active APJ receptor agonist (K_d = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr ¹) apelin-13. BMS-986224 has the potential for the research of heart failure .

HY-113168

Butyrylcarnitine 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .

HY-B0247

Torsemide 1 Publications Verification Torasemide	NKCC	Cardiovascular Disease Metabolic Disease
Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-148087

AZD5462 1 Publications Verification	RXFP Receptor	Cardiovascular Disease
AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties .

HY-A0154

Deslanoside Deacetyllanatoside C; Desacetyllanatoside C	Na+/K+ ATPase Drug Metabolite	Cardiovascular Disease
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .

HY-119515

Denopamine (R)-(-)-Denopamine; TA-064	Adrenergic Receptor	Cardiovascular Disease Cancer
Denopamine ((R)-(-)-Denopamine) is an orally active, selective β1-adrenergic agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects .

HY-131180

BMS-986235 1 Publications Verification LAR-1219	Formyl Peptide Receptor (FPR)	Cardiovascular Disease
BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC₅₀s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure .

HY-109121

Reldesemtiv 2 Publications Verification CK-2127107	Calcium Channel	Cardiovascular Disease
Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC₅₀ of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model .

HY-B1469

Isosorbide 1 Publications Verification D-Isosorbide; Dianhydro-D-glucitol	Calcium Channel	Cardiovascular Disease Metabolic Disease
Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic .

HY-110273

N106 1 Publications Verification	Calcium Channel E1/E2/E3 Enzyme	Cardiovascular Disease
N106 is a first-in-class sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research .

HY-113071

Mevalonic acid MVA	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-120274

Balcinrenone AZD9977	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research .

HY-14254A

Olprinone 1 Publications Verification Loprinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-14304A

Zinterol hydrochloride 1 Publications Verification MJ 9184 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist . Zinterol hydrochloride increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM . Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits .

HY-144439

HTS07545	Mitochondrial Metabolism	Cardiovascular Disease Cancer
HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC₅₀ of 30 nM. HTS07545 reduces the decomposition rate of hydrogen sulfide (H₂S). HTS07545 can be used in the research of heart failure and pancreatic ductal adenocarcinoma.

HY-126236

3,5-Diiodothyropropionic acid 1 Publications Verification	Thyroid Hormone Receptor	Cardiovascular Disease Endocrinology
3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with K_a of 2.40 and 4.06 M ^-1 for TRα1 and TRβ1, respectively. 3,5-Diiodothyropropionic acid promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay. 3,5-Diiodothyropropionic acid prevents myocardial arteriolar loss in thyroidectomized rats and enhances cardiac energy-generating capacity in postinfarction heart failure rats. 3,5-Diiodothyropropionic can be used in studies related to angiogenesis and heart failure .

HY-14254

Olprinone Hydrochloride 1 Publications Verification Loprinone Hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-134908

DHNA 1,4-Dihydroxy-6-naphthoic acid	PDHK	Cardiovascular Disease
DHNA (KIS20) is a PDH kinase 4 (PDK4) inhibitor with an IC₅₀ of 18 μM. DHNA can be used for the study of heart failure .

HY-135363

Valsartan Ethyl Ester 2 Publications Verification	Angiotensin Receptor	Cardiovascular Disease
Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure .

HY-119608

GSK854	MAP3K	Cardiovascular Disease
GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure .

HY-119816

Piretanide	NKCC	Cardiovascular Disease
Piretanide is an oral active, relatively safe and effective diuretic. Piretanide has the potential for the research of congestive heart failure with a potential advantage of having potassium-sparing properties. Piretanide can also be used for the research of hypertension ^[1] ^[2].

HY-W414915

Valsartan methyl ester CGP 48933 methyl ester	Drug Derivative Angiotensin Receptor	Cardiovascular Disease Cancer
Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-124873

SERCA2a activator 1	Calcium Channel	Cardiovascular Disease
SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca ²⁺-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure .

HY-165578

Neladenoson	Adenosine Receptor	Cardiovascular Disease Neurological Disease Cancer
Neladenoson is a potent and selective Adenosine A1 Receptor agonist. Neladenoson is promising for research of heart failure .

HY-162897

BAY-2413555	mAChR	Cardiovascular Disease
BAY-2413555 is an orally active muscarinic acetylcholine receptor M2 modulator that protects the heart and improve cardiac function. BAY-2413555 is promising for research of heart failure .

HY-18347

Conivaptan YM 087 free base	Vasopressin Receptor	Cardiovascular Disease
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .

HY-14252A

Milrinone lactate 30+ Cited Publications Win 47203 lactate	Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock .

HY-165439

Indolidan LY195115	Phosphodiesterase (PDE)	Cardiovascular Disease
Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a K_i of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure .

HY-119817

Flosequinan BTS 49465; Flosequinon	PKC	Cardiovascular Disease
Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure .

HY-160706

HHQ16	Drug Derivative	Cardiovascular Disease
HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling .

HY-120577

BA 41899	Others	Cardiovascular Disease
BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF) .

HY-153168

Bemoradan	Phosphodiesterase (PDE)	Cardiovascular Disease
Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research .

HY-145552

Azilsartan mepixetil QR-01019	Angiotensin Receptor	Cardiovascular Disease
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-106565

Meproscillarin Methylproscillaridin	Endogenous Metabolite	Cardiovascular Disease
Meproscillarin (Methylproscillaridin) is a glycoside. Meproscillarin can be used for research of heart failure .

HY-112072

Ibopamine hydrochloride SB 7505 hydrochloride; SKF 100168 hydrochloride	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Ibopamine (SB 7505) hydrochloride is an orally active dopamine derivative. Ibopamine hydrochloride exerts agonistic effects on α, β adrenergic receptors and dopaminergic receptors. Ibopamine hydrochloride can be hydrolyzed to produce the active metabolite Epinine. Ibopamine hydrochloride possesses positive inotropic and vasodilatory effects, which can improve hemodynamics and renal function in heart failure models. Ibopamine hydrochloride has good safety profile and can be used in the research of diseases such as congestive heart failure .

HY-118605

Aminometradine	Sodium Channel Chloride Channel	Cardiovascular Disease Endocrinology
Aminometradine is an orally active diuretic. Aminometradine increases urine volume and the excretion of sodium and chloride. Aminometradine can be used in studies of congestive heart failure .

HY-105057

MDL 19205	Phosphodiesterase (PDE)	Cardiovascular Disease
MDL 19205 is a cardiotonic agent with inotropic effect. MDL 19205 can be used for the research of cardiovascular disease, such as heart failure .

HY-147384

CXL-1020	Calcium Channel	Cardiovascular Disease
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca ²⁺ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure .

HY-15407BR

Sacubitril sodium (Standard) AHU-377 sodium (Standard)	Reference Standards Neprilysin	Infection Cardiovascular Disease
Sacubitril (sodium) (Standard) is the analytical standard of Sacubitril (sodium). This product is intended for research and analytical applications. Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19 .

HY-109034A

Imarikiren hydrochloride	Renin	Cardiovascular Disease
Imarikiren hydrochloride is a renin inhibitor. Imarikiren hydrochloride can be used for the study of cardiovascular and renal diseases such as hypertension, heart failure, and diabetic nephropathy by blocking the renin-angiotensin (RA) system .

HY-A0230A

Spirapril hydrochloride SCH 33844 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .

HY-137387

Carvedilol Glucuronide	Drug Metabolite	Cardiovascular Disease Others
Carvedilol Glucuronide is the metabolite of Carvedilol (HY-B0006). Carvedilol (BM 14190) is an antagonist for β/α-1 adrenergic receptor. Carvedilol inhibits lipid peroxidation with an IC₅₀ of 5 μM. Carvedilol is an antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .

HY-174256

GRL-098-22	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease Cancer
GRL-098-22 (Compound 6t) is a potent inhibitor targeting G protein-coupled receptor kinase 5 (GRK5) and GRK6 with IC₅₀ values of 0.6 μM and 0.19 μM, respectively. GRL-098-22 is promising for research of diseases such as heart failure and multiple myeloma .

Cat. No.	Product Name

HY-L185

Anti-Fibrosis Compound Library

2,415 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 2,415 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

HY-L087

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L923

Ion Channel Lead-like Compound Library

9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Cat. No.	Product Name	Type

HY-D0098

Fluorescein-5-maleimide

5 Publications Verification

N-(5-Fluoresceinyl)maleimide

Fluorescent Dye

Fluorescein-5-maleimide (N-(5-Fluoresceinyl)maleimide) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiac myosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm .

HY-12879G

IWP-4

Fluorescent Dye

IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

HY-DY1088

Fluorescein-5-maleimide (solution)

N-(5-Fluoresceinyl)maleimide (solution)

Fluorescent Dye

Fluorescein-5-maleimide (solution) (N-(5-Fluoresceinyl)maleimide (solution)) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiac myosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm .

Solvent and concentration: DMSO: 10 mM

Cat. No.	Product Name	Type

HY-112537A

D-Glucose 6-phosphate dipotassium

Biochemical Assay Reagents

D-Glucose 6-phosphate dipotassium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate dipotassium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate dipotassium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure .

HY-12879G

IWP-4

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P0003

Nesiritide Brain Natriuretic Peptide-32 human; BNP-32	Natriuretic Peptide Receptor (NPR) Calcium Channel	Cardiovascular Disease
Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with K_d values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V_1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury .

HY-121705

Propionyl-L-carnitine	Endogenous Metabolite Apoptosis Bcl-2 Family NF-κB Survivin Src Akt AMPK NO Synthase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis .

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-P3304

MR 409	GHSR	Neurological Disease Cancer
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer .

HY-P3436

WLSEAGPVVTVRALRGTGSW	Exosomes	Cardiovascular Disease
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-P0190A

Iberiotoxin TFA 2 Publications Verification	Potassium Channel	Others
Iberiotoxin (TFA) is a selective high conductance high conductance Ca ²⁺-activated K ⁺ channel inhibitor with a K_d of ~1 nM. Iberiotoxin (TFA) does not block other types of voltage-dependent ion channels .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-P11206A

Murine cardiac troponin I peptide TFA Murine cardiac TnI peptide TFA	Peptides	Inflammation/Immunology
Murine cardiac troponin I peptide (Murine cardiac TnI peptide) TFA is a murine cardiac troponin I (cTnI) peptide. Murine cardiac troponin I peptide TFA can induce significant myocardial inflammation followed by fibrosis and heart failure with increased mortality in mice model. Murine cardiac troponin I peptide TFA can be used for heart failure research .

HY-P3429A

SAMβA TFA	PKC	Cardiovascular Disease
SAMβA TFA is a rationally designed selective antagonist of Mfn1-βIIPKC association and can bind to TAT (HY-P0281). SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .

HY-P3429

SAMβA	PKC	Cardiovascular Disease
SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .

HY-P3678

Neuropeptide Y (18-36) (porcine)	Neuropeptide Y Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC₅₀ value of 158 nM and an K_i value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure .

HY-P11206

Murine cardiac troponin I peptide Murine cardiac TnI peptide	Peptides	Cardiovascular Disease Inflammation/Immunology
Murine cardiac troponin I peptide (Murine cardiac TnI peptide) is a murine cardiac troponin I (cTnI) peptide. Murine cardiac troponin I peptide can induce significant myocardial inflammation followed by fibrosis and heart failure with increased mortality in mice model. Murine cardiac troponin I peptide can be used for heart failure research .

HY-P2687

Ularitide Urodilatin (human)	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Ularitide (Urodilatin), natriuretic peptide, is a vasodilator. Ularitide binds to and activates renal receptors. Ularitide also regulates renal dopamine metabolism Ularitide can be used in the research of heart failure .

HY-P10259

BNP(1-32), porcine pBNP-32	Natriuretic Peptide Receptor (NPR)	Neurological Disease
BNP(1-32), porcine (pBNP-32) is a cardiac hormone. BNP(1-32), porcine is an atrial natriuretic peptide, which exhibits natriuretic, diuretic and vasorelaxant effects. BNP(1-32), porcine affects passive avoidance learning in rats with dopaminergic, cholinergic, α-and β-adrenergic mediation .

HY-P3557

Mibenratide	Adrenergic Receptor	Cardiovascular Disease
Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research .

HY-120521

Urodilatin	Natriuretic Peptide Receptor (NPR)	Neurological Disease
Urodilatin is an analogue of ANF-(99-126). Urodilatin is a diuretic-natriuretic regulatory peptide. Urodilatin can be used for research of acute renal failure, congestive heart failure, and bronchial asthma, etc .

HY-P3557A

Mibenratide TFA	Adrenergic Receptor	Cardiovascular Disease
Mibenratide TFA, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide TFA can be used for heart failure research .

HY-P11041

VS-IP1	STAT	Cardiovascular Disease
VS-IP1 is an interfering peptide that blocks viperin-mediated STAT1 degradation, thereby preventing coxsackievirus B3 (CVB3)-induced acute heart failure (AHF) .

HY-P3436A

WLSEAGPVVTVRALRGTGSW TFA	Exosomes	Cardiovascular Disease
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .

HY-P3868A

QEQLERALNSS TFA	Apoptosis	Cardiovascular Disease
QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis .

HY-P0003A

Nesiritide acetate Brain Natriuretic Peptide-32 human acetate; BNP-32 acetate	Natriuretic Peptide Receptor (NPR) Calcium Channel	Cardiovascular Disease
Nesiritide (Brain Natriuretic Peptide-32 human) acetate is a recombinant human B-type natriuretic peptide. Nesiritide acetate is a NPRs agonist, with K_d values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide acetate regulates V_1/2 activation/inactivation of the L-type calcium channel. Nesiritide acetate shows vasodilatory, diuretic, and natriuretic activities. Nesiritide acetate is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury .

HY-P11625

R9-13	RXFP Receptor	Cardiovascular Disease
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99139

Anti-Mouse IL-1b Antibody (B122)	Interleukin Related Reactive Oxygen Species (ROS) Ferroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .

HY-P99177

Enibarcimab	Inhibitory Antibodies	Cardiovascular Disease Infection
Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure .

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-P99645

Goflikicept RPH 104	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) .

HY-P992108

Efadirelaxin alfa RELAX10	RXFP Receptor Akt NO Synthase VEGFR	Cardiovascular Disease
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2333

Resiniferatoxin 5+ Cited Publications (+)-Resiniferatoxin	Cardiovascular Disease Structural Classification Euphorbia resinifera O. Berg Monophenols Classification of Application Fields Phenols Euphorbiaceae Plants Disease Research Fields Source Classification	TRP Channel
Resiniferatoxin ((+)-Resiniferatoxin), is a selective agonist of transient receptor potential vanilloid 1 (TRPV1) receptor agonist. Resiniferatoxin can be isolated from the Euphorbia resinifera plant. Resiniferatoxin eliminates TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period .

HY-113071A

Mevalonic acid lithium salt 5+ Cited Publications MVA lithium salt	Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-B1357

Digitoxin 5+ Cited Publications	Digitalis purpurea Linn. Cardiovascular Disease Structural Classification Classification of Application Fields Scrophulariaceae Plants Disease Research Fields Steroids Source Classification	Environmental Pollutants Apoptosis Na+/K+ ATPase Bcl-2 Family Caspase HSV Calcium Channel
Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .

HY-18206

Lisinopril 5 Publications Verification MK-521	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Angiotensin-converting Enzyme (ACE)
Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.

HY-N0716B

Berberine sulfate Maximum Cited Publications 77 Publications Verification Natural Yellow 18 sulfate	Alkaloids Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification	Antibiotic Topoisomerase Autophagy Bacterial Reactive Oxygen Species (ROS) Parasite Apoptosis PI3K Akt Caspase JNK AP-1 NF-κB
Berberine sulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine sulfate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine sulfate has antineoplastic properties. The sulfate form improves bioavailability .

HY-B0251

Eplerenone 5+ Cited Publications Epoxymexrenone	Cardiovascular Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Mineralocorticoid Receptor Endogenous Metabolite
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-112537

D-Glucose 6-phosphate 4 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite mTOR
D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure .

HY-N0217

Benzoylaconine 1 Publications Verification Benzoylaconitine; Isaconitine; Pikraconitin	Alkaloids Classification of Application Fields Other Alkaloids Ranunculaceae Other Diseases Aconitum carmichaeli Debx. Plants Disease Research Fields Source Classification	Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Toll-like Receptor (TLR) NF-κB COX NO Synthase p38 MAPK P-glycoprotein
Benzoylaconine (Benzoylaconitine) is an orally active monoester alkaloid found in the traditional Chinese medicine Aconitum carmichaelii. Benzoylaconine is an ACE2 agonist (EC₅₀: 1.5 μM) with antihypertensive and anti-heart failure effects. Benzoylaconine inhibits TLR-induced MAPK and NF-κB pathways to exert anti-inflammatory effects. Benzoylaconine upregulates the protein levels of P-gp, MRP2, and has anti-tumor effects .

HY-N2037

Higenamine 5+ Cited Publications Norcoclaurine; Demethyl-Coclaurine	Alkaloids Structural Classification Classification of Application Fields Ranunculaceae Phenols Polyphenols Aconitum carmichaeli Debx. Plants Isoquinoline Alkaloids Disease Research Fields Endocrinology Source Classification	MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-B1030

Lanatoside C 5+ Cited Publications	other families Classification of Application Fields Cardiacglycosides Plants Disease Research Fields Steroids Source Classification Cancer	Flavivirus Dengue Virus Autophagy Enterovirus
Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .

HY-113168

Butyrylcarnitine 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .

HY-A0154

Deslanoside Deacetyllanatoside C; Desacetyllanatoside C	Digitalis purpurea Linn. Cardiovascular Disease Structural Classification Classification of Application Fields Cardiacglycosides Scrophulariaceae Plants Disease Research Fields Steroids Source Classification	Na+/K+ ATPase Drug Metabolite
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .

HY-B0642

Isosorbide mononitrate 5 Publications Verification Isosorbide-5-mononitrate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Autophagy Endogenous Metabolite Apoptosis
Isosorbide mononitrate (Isosorbide-5-mononitrate) is an orally active nitric acid compound used for angina pectoris by dilating blood vessels and lowering blood pressure. Isosorbide mononitrate increases the viability and proliferation of HUVECs by decreasing Apoptosis and elevated the expressions of vedf, kdrl, pdgfr in zebrafish embryos. Isosorbide mononitrate is promising for research of heart failure and coronary heart disease .

HY-N0559

Kirenol 1 Publications Verification	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .

HY-A0115

Ramiprilat HOE 498 diacid; Ramipril diacid	Cardiovascular Disease Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Drug Metabolite Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a K_i value of 7 pM. Ramiprilat has acute antlhypertensive effect. Ramiprilat can be used for high blood pressure and heart failure research .

HY-N0712

Typhaneoside 3 Publications Verification	Cardiovascular Disease Flavonols Structural Classification Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Autophagy mTOR Akt FXR
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G₂/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .

HY-N0716A

Berberine hemisulfate 50+ Cited Publications Natural Yellow 18 hemisulfate	Infection Alkaloids Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Source Classification Cancer	Antibiotic Topoisomerase Autophagy Bacterial Reactive Oxygen Species (ROS) Apoptosis PI3K Akt Caspase JNK AP-1 NF-κB
Berberine hemisulfate is the hemisulfate form of Berberine (HY-N0716). Berberine hemisulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian. Berberine hemisulfate exhibits anti-inflammatory, antibiobic, antitumor, cardiovascular protective and neuroprotective activity .

HY-N0716

Berberine Natural Yellow 18	Classification of Application Fields Anti-aging Ranunculaceae Plants Endogenous metabolite Biological Pesticide Research Agricultural Research Alkaloids Coptis chinensis Franch. Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification Cancer	Antibiotic Topoisomerase Autophagy Bacterial Reactive Oxygen Species (ROS) Parasite Apoptosis PI3K Akt Caspase JNK AP-1 NF-κB
Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties. The sulfate form (HY-N0716B) improves bioavailability .

HY-113071

Mevalonic acid MVA	Human Gut Microbiota Metabolites Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Other Diseases Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-N0107

Cyclovirobuxine D 1 Publications Verification	Cardiovascular Disease Alkaloids Buxaceae Classification of Application Fields Other Alkaloids Plants Disease Research Fields Buxus microphylla S.et Z.var. Sinica Rehd.et Wils.	Apoptosis Autophagy mTOR Akt
Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-136933

Gitoxin	Digitalis purpurea Linn. Cardiovascular Disease Structural Classification Classification of Application Fields Scrophulariaceae Plants Disease Research Fields Steroids Source Classification	Na+/K+ ATPase
Gitoxin is a degradation metabolite of Digitoxin (HY-B1357) and a non-competitive Na ⁺/K ⁺-ATPase inhibitor, with an IC₅₀ of 1.18e-6 M against the porcine high-affinity subtype and an IC₅₀ of 2.85e-5 M against the porcine low-affinity subtype. Gitoxin regulates atrial contractility and rhythmicity. Gitoxin is applicable to research related to congestive heart failure .

HY-B0093

Benazepril 2 Publications Verification CGS14824A free base	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)
Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-N13250

Hawthorn Extract	Cardiovascular Disease Classification of Application Fields Rosaceae Plants Disease Research Fields Source Classification	Apoptosis AMPK Elastase Bcl-2 Family Interleukin Related Caspase PI3K Akt SOD
Hawthorn Extract is an orally active hawthorn extract. Hawthorn Extract decreases Bax expression and increases Bcl-2 expression in the aorta. Hawthorn Extract regulates the AMPK signaling pathway, induces apoptosis, enhances the hepatic antioxidant system, and ameliorates symptoms of liver injury, inflammation and cancer. Hawthorn Extract reduces plasma levels of pro-inflammatory factors, increases plasma levels of anti-inflammatory adiponectin, and alleviates atherosclerotic plaque lesions in the aorta. Hawthorn Extract improves symptoms associated with chronic heart failure . Hawthorn Extract inhibits FMLP-induced superoxide anion production, Elastase release, ILB₄ generation and calcium signaling in neutrophils, and also reduces LPS-induced cytokine production in neutrophils. Hawthorn Extract induces autophagy and inhibits the proliferation of intestinal stem cells. Hawthorn Extract can be used in research related to atherosclerosis, hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, chronic heart failure and hypotension .

HY-N3312

Matairesinol	Infection Structural Classification other families Classification of Application Fields Anti-aging Lignans Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification	p38 MAPK JNK NF-κB
Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer .

HY-156193

PF-07208254	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	PDHK
PF-07208254 is a selective, orally active allosteric inhibitor of branched-chain ketoacid dehydrogenase kinase (BDK) (IC₅₀=110 nM, K_i=54 nM, K_D=84 nM). PF-07208254 inhibits BDK-mediated BCKDH phosphorylation and enhances the catabolism of branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs) by binding to the allosteric pocket of BDK, reducing BDK binding to BCKDH-E2 and promoting BDK degradation. PF-07208254 inhibits BDK activity in human skeletal muscle cells (IC₅₀=540 nM) and has activity to improve cardiac function and metabolism. PF-07208254 can be used in the study of cardiometabolic diseases (e.g., heart failure, type 2 diabetes) .

HY-155157

PF-07247685	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-113495

Deoxypyridinoline	Cardiovascular Disease Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Deoxypyridinoline is an endogenous metabolite present in Urine that can be used for the research of Heart Failure .

HY-112817

8-Oxo-dGTP 8-Oxo-Deoxyguanosine triphosphate	Microorganisms Source Classification	Apoptosis
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .

HY-132187

Sphingosylphosphorylcholine	Structural Classification Natural Products Endogenous metabolite Source Classification	TGF-beta/Smad TRP Channel Apoptosis PAI-1
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a K_d of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .

HY-16022

Acetyldigitoxin Digitoxin 3'''-Acetate	Plantaginaceae Cardiacglycosides Stauranthus perforatus Plants Steroids Source Classification	Others
Acetyldigitoxin (Digitoxin 3'''-Acetate) is a cardiac glycoside. Acetyldigitoxin can come from the leaves of Digitalis species. Acetyldigitoxin reduces the heart rate and can be used for cardiac failure rasearch .

HY-B1357R

Digitoxin (Standard)	Digitalis purpurea Linn. Structural Classification Microorganisms Scrophulariaceae Plants Steroids Source Classification	Reference Standards Bcl-2 Family Caspase Apoptosis HSV Na+/K+ ATPase Calcium Channel
Digitoxin (Standard) is the analytical standard of Digitoxin. This product is intended for research and analytical applications. Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .

HY-A0115R

Ramiprilat (Standard) HOE 498 diacid (Standard); Ramipril diacid (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-N15744

*Anti-Heart* Failure Agent 3**	Cornaceae Cornus officinalis Sieb. et Zucc. Ketones, Aldehydes, Acids Plants Source Classification	NO Synthase
Anti-Heart Failure Agent 3 (Compound 2) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 3 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 3 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 3 is promising for research of heart failure .

HY-N2037R

Higenamine (Standard) Norcoclaurine (Standard); Demethyl-Coclaurine (Standard)	Alkaloids Structural Classification Ranunculaceae Phenols Polyphenols Aconitum carmichaeli Debx. Plants Isoquinoline Alkaloids Source Classification	Reference Standards MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N13747

Chrysosplenol C	Structural Classification Flavonoids Asteraceae Miliusa balansae Finet & Gagnep. Pterocaulon sphacelatum (Labill.) Benth. & Hook.f. ex F.Muell. Plants Annonaceae Other Flavonoids Source Classification	Myosin PKC Calcium Channel
Chrysosplenol C is a type of flavonoid compound. Chrysosplenol C selectively activates cardiac myosin ATPase, with its EC₅₀ being 45 µM. Chrysosplenol C enhances the release of intracellular calcium ions by activating protein kinase C (PKC), thereby increasing the contractility of rat ventricular muscle cells. Chrysosplenol C can be used in the research of heart failure .

HY-B1030R

Lanatoside C (Standard)	Structural Classification other families Cardiacglycosides Plants Steroids Source Classification	Dengue Virus Flavivirus Reference Standards CHIKV Autophagy Enterovirus
Lanatoside C (Standard) is the analytical standard of Lanatoside C. This product is intended for research and analytical applications. Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-113071AR

Mevalonic acid lithium salt (Standard) MVA lithium salt (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-A0154R

Deslanoside (Standard) Deacetyllanatoside C (Standard); Desacetyllanatoside C (Standard)	Digitalis purpurea Linn. Structural Classification Cardiacglycosides Scrophulariaceae Plants Steroids Source Classification	Reference Standards Na+/K+ ATPase Drug Metabolite
Deslanoside (Standard) is the analytical standard of Deslanoside. This product is intended for research and analytical applications. Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .

HY-N15745

*Anti-Heart* Failure Agent 4**	Cornaceae Cornus officinalis Sieb. et Zucc. Ketones, Aldehydes, Acids Plants Source Classification	NO Synthase
Anti-Heart Failure Agent 4 (Compound 3) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 4 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 4 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 4 is promising for research of heart failure .

HY-N15743

*Anti-Heart* Failure Agent 2**	Cornaceae Cornus officinalis Sieb. et Zucc. Ketones, Aldehydes, Acids Plants Source Classification	NO Synthase
Anti-Heart Failure Agent 2 (Compound 1) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 2 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 2 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 2 is promising for research of heart failure .

HY-B1746R

Pyridoxamine 5′-phosphate (Standard)	Alkaloids Human Gut Microbiota Metabolites Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Sacubitril (sodium) (Standard) is the analytical standard of Sacubitril (sodium). This product is intended for research and analytical applications. Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19 .

HY-N0859A

Schisanhenol B	Lignans Phenols Phenylpropanoids Kadsura coccinea (Lem.) A. C. Smith Plants Schisandraceae Source Classification	PI3K Tyrosinase
Schisanhenol B is one of the active ingredients of schisandra chinensis. Schisanhenol B is a tyrosinase inhibitor. Schisanhenol B has good binding activity with PIK3CG and can be used in the study of heart failure .

HY-113168R

Butyrylcarnitine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine (HY-113168). This product is intended for research and analytical applications. Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .

HY-N0107R

Cyclovirobuxine D (Standard)	Structural Classification Alkaloids Buxaceae Other Alkaloids Plants Buxus microphylla S.et Z.var. Sinica Rehd.et Wils.	Reference Standards Apoptosis Autophagy mTOR Akt
Cyclovirobuxine D (Standard) is the analytical standard of Cyclovirobuxine D. This product is intended for research and analytical applications. Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-N0716BR

Berberine sulfate (Standard) Natural Yellow 18 sulfate (Standard)	Alkaloids Structural Classification Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Reference Standards Antibiotic Topoisomerase Autophagy Bacterial Reactive Oxygen Species (ROS) Parasite Apoptosis PI3K Akt Caspase JNK AP-1 NF-κB
Berberine (sulfate) (Standard) is the analytical standard of Berberine (sulfate). This product is intended for research and analytical applications. Berberine sulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine sulfate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine sulfate has antineoplastic properties. The sulfate form improves bioavailability[1][2].

HY-N0716AR

Berberine hemisulfate (Standard) Natural Yellow 18 hemisulfate (Standard)	Structural Classification Alkaloids Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Reference Standards Antibiotic Topoisomerase Autophagy Bacterial Reactive Oxygen Species (ROS) Apoptosis PI3K Akt Caspase JNK AP-1 NF-κB
Berberine (hemisulfate) (Standard) is the analytical standard of Berberine (hemisulfate). This product is intended for research and analytical applications. Berberine hemisulfate is the hemisulfate form of Berberine (HY-N0716). Berberine hemisulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian. Berberine hemisulfate exhibits anti-inflammatory, antibiobic, antitumor, cardiovascular protective and neuroprotective activity .

HY-N0559R

Kirenol (Standard)	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Reference Standards Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol (Standard) is the analytical standard of Kirenol (HY-N0559). This product is intended for research and analytical applications. Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

HY-165346

Cuspidoside	Structural Classification Cardiacglycosides Convallaria majalis L. Plants Steroids Asparagaceae Juss. Source Classification	Others
Cuspidoside is a cardiac glycoside and can be used for the research of cardiovascular disease, such as heart failure .

Cat. No.	Product Name	Chemical Structure

HY-15407S

Sacubitril-d4
Sacubitril-d₄ is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

HY-B0932S2

Levocarnitine propionate-d9 hydrochloride
Levocarnitine propionate-d₉ hydrochloride (L-Propionylcarnitine-d₉ chloride) is deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride is used to study diseases such as renal function deterioration, congestive heart failure, and intermittent claudication .

HY-112537S1

D-Glucose 6-Phosphate-13C6 (disodium xhydrate)

D-Glucose 6-Phosphate- ¹³C₆ disodium xhydrate is a ¹³C-labeled D-Glucose 6-phosphate disodium xhydrate. D-Glucose 6-phosphate disodium xhydrate is a key central node metabolite in sugar metabolism, serving as the initial metabolite of glycolysis and pentose phosphate pathway, and also a substrate for glycogen synthesis. D-Glucose 6-phosphate disodium xhydrate can act as a metabolic stress signal, especially when phosphoglucomutase (PGI) is inhibited, activating the mTOR pathway, promoting protein synthesis, and thereby participating in the remodeling process of the heart. D-Glucose 6-phosphate disodium xhydrate can be used in research related to non-insulin-dependent diabetes and heart failure.

HY-B0932S

Levocarnitine propionate-d3 hydrochloride
Levocarnitine propionate-d₃ (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.

HY-B0135S

Furosemide-d5

Furosemide-d₅ is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl-?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-18204S2

Valsartan-d8
Valsartan-d₈ is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research .

HY-B0006S1

Carvedilol-d4

Carvedilol-d₄ is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker . Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC₅₀ of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .

HY-112537S2

D-Glucose 6-phosphate-13C

D-Glucose 6-phosphate- ¹³C is ¹³C labeled D-Glucose 6-phosphate (HY-112537). D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.

HY-18204S

Valsartan-d9
Valsartan-d₉ is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research .

HY-18204S1

Valsartan-d3
Valsartan-d₃ is the deuterium labeled Valsartan . Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research .

HY-B0247S

Torsemide-d7
Torsemide-d₇ is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-A0115S1

Ramiprilat-d5
Ramiprilat-d₅ is deuterium labeled Ramiprilat. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a K_i value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research .

HY-B0202S

Irbesartan-d4

Irbesartan-d₄ (SR-47436-d₄) is the deuterium labeled Irbesartan Irbesartan (HY-B0202). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.

HY-18206S

Lisinopril-d5
Lisinopril-d₅ is the deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.

HY-B0251S

Eplerenone-d3
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC₅₀ of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .

HY-12717AS

Phentolamine-d4 hydrochloride

Phentolamine-d₄ (hydrochloride) is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction .

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-B0251S1

Eplerenone-13C,d3

Eplerenone- ¹³C,d₃ (Epoxymexrenone- ¹³C,d₃) is ¹³C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-B0374S

Moxonidine-d4

Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0592S

Trandolapril-d5
Trandolapril-d₅ is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF) .

HY-A0115S2

Ramiprilat-d4 hydrochloride
Ramiprilat-d₄ hydrochloride is deuterated labeled Ramiprilat (HY-A0115). Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research .

HY-15407S3

Sacubitril-13C4
Sacubitril-13C4 (AHU-377-13C4) is a 13C-labeled version of Sacubitril (HY-15407). Sacubitril is an orally active inhibitor of neprilysin NEP (IC₅₀=5 nM). Sacubitril is used in research on heart failure, hypertension and COVID-19 .

HY-B0202AS

Irbesartan-d7 hydrochloride

Irbesartan-d₇ hydrochloride is deuterated labeled Irbesartan hydrochloride (HY-B0202A). Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-B0202S3

Irbesartan-d7
Irbesartan-d₇ is deuterated labeled Irbesartan (HY-B0202). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-18206S1

(S)-Lisinopril-d5 sodium
(S)-Lisinopril-d₅ (sodium) (MK-521-d₅ (sodium)) is deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.

HY-B0209S

Metolazone-d7
Metolazone-d₇ is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.

HY-18206S2

Lisinopril-13C5,15N
Lisinopril- ¹³C₅, ¹⁵N (MK-521- ¹³C₅, ¹⁵N) is ¹³C and ¹⁵N labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.

HY-18204S3

(Rac)-Valsartan-d9
(Rac)-Valsartan-d₉ is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research .

HY-117281S

Moexipril-d5
Moexipril-d₅ is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure .

HY-B0932S1

Levocarnitine propionate-d5 hydrochloride
Levocarnitine propionate-d₅ (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.

HY-100713S

Temocapril-d5
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-A0043S2

Cilazapril-d5 trifluoroacetate
Cilazapril-d₅ (Ro 31-2848-d₅) trifluoroacetate is the deuterium labeled Cilazapril (HY-A0043). Cilazapril is an angiotensin-converting enzyme (ACE) inhibitor used for the study of hypertension and congestive heart failure.

HY-B0130S

Perindopril-d4 erbumine
Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease .

HY-15407AS

Sacubitril-13C4 hemicalcium salt
Sacubitril- ¹³C₄ (hemicalcium salt) is a ¹³C-labeled and deuterium labeled Sacubitril hemicalcium salt. Sacubitril (AHU-377) hemicalcium salt is a potent NEP inhibitor with an IC₅₀ of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696 .

HY-B0202S2

Irbesartan-d6-1
Irbesartan-d₆-1 is the deuterium labeled Irbesartan . Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-145552S

Azilsartan mepixetil-d5

Azilsartan mepixetil-d₅ (QR-01019-d₅) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-W716688

Isosorbide-d8
Isosorbide-d₈ is the deuterium labeled Isosorbide (HY-B1469). Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic .

HY-152007S

Butyrylcarnitine-d3 hydrochloride

Butyrylcarnitine-d₃ hydrochloride is deuterium labeled Butyrylcarnitine (HY-113168). Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .

HY-15407AS1

Sacubitril-d4 hemicalcium salt
Sacubitril-d₄ hemicalcium salt is the deuterium labeled Sacubitril hemicalcium salt (HY-15407A). Sacubitril hemicalcium salt is a potent NEP inhibitor with an IC₅₀ of 5 nM .

HY-78841S

(2S,4S)-Sacubitril-d4
(2S,4S)-Sacubitril-d₄ is deuterium labeled (2S,4S)-Sacubitril. (2S,4S)-Sacubitril is the impurity of Sacubitril. Sacubitril is a potent NEP inhibitor that can be used for the research of heart failure .

HY-W744298

Trandolapril-d3
Trandolapril-d₃ is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0006S

Carvedilol-d3

Carvedilol-d₃ is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker . Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC₅₀ of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .

HY-B0592S2

rac-Trandolapril-d5

rac-Trandolapril-d₅ (rac-RU44570-d₅) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0006S2

Carvedilol-d5
Carvedilol-d₅ is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker . Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC₅₀ of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .

HY-B0093AS

Benazepril-d5 hydrochloride

Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-W755778

3-Iodothyronamine hydrochloride-13C6

3-Iodothyronamine hydrochloride- ¹³C₆ is the ¹³C-labeled 3-Iodothyronamine hydrochloride (HY-135065). 3-Iodothyronamine hydrochloride is an endogenous and rapid-acting derivative of thyroid hormone. 3-Iodothyronamine potently activates an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale. 3-Iodothyronamine can be used for the research of congestive heart failure .

HY-B0368S

Captopril-d3

Captopril-d₃ is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC₅₀ of 7.9 μM .

HY-W755679

Digitoxigenin-21,23,23-d3

Digitoxigenin-21,23,23-d₃ (Cerberigenin-d₃; Echujetin-d₃) is the deuterium labeled Digitoxigenin (HY-B2151). Digitoxigenin is a steroid derivative commonly found in various plants, especially the foxglove plant (Digitalis purpurea). Digitoxigenin has unique chemical properties that make it an important precursor for the synthesis of cardiac glycosides, a group of drugs used to improve heart failure and certain types of arrhythmias. It works by inhibiting the sodium potassium ATPase pump, thereby increasing the force and efficiency of cardiac contractions.

HY-B0374S1

Moxonidine-d7

Moxonidine-d₇ is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0368S1

Captopril-13C5,15N

Captopril- ¹³C₅, ¹⁵N (SQ 14225- ¹³C₅, ¹⁵N) is ¹³C and ¹⁵N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC₅₀ of 7.9 μM .

Cat. No.	Product Name		Classification

HY-185317A

Dimovarsen sodium		Antisense Oligonucleotides
Dimovarsen sodium, an oligonucleotide, is a micro RNA-132 inhibitsor, and can be use for the study of heart failure.

HY-185317

Dimovarsen		Antisense Oligonucleotides
Dimovarsen, an oligonucleotide, is a micro RNA-132 inhibitsor, and can be use for the study of heart failure.

HY-112817A

8-Oxo-dGTP trisodium solution (100 mM) 8-Oxo-Deoxyguanosine triphosphate trisodium		Nucleotide Analogs Guanine Nucleotide
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12879G

IWP-4	Wnt Casein Kinase	Cardiovascular Disease Neurological Disease Cancer
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Heart Failure

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products